-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Iterum Therapeutics to Neutral

Benzinga·03/30/2026 17:31:05
Listen to the news
HC Wainwright & Co. analyst Matthew Keller downgrades Iterum Therapeutics (NASDAQ:ITRM) from Buy to Neutral.